Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Patricia G. Synnott"'
Publikováno v:
Health Policy Open, Vol 4, Iss , Pp 100093- (2023)
Growth in the cost of prescription drugs in the US has generated significant interest in the use of external reference pricing (ERP) to tie prices paid for drugs to those in other countries. We used data from the Pricentric ONE™ database, an intern
Externí odkaz:
https://doaj.org/article/1c8c6d33a4db457cbf8ff13b3adc139c
Publikováno v:
BMJ Global Health, Vol 6, Iss 6 (2021)
Introduction Cost-effectiveness analysis (CEA) is critical for identifying high-value interventions that address significant unmet need. This study examines whether CEA study volume is proportionate to the burden associated with 21 major disease cate
Externí odkaz:
https://doaj.org/article/585857504e9b4d40bd38f71b296ed40f
Publikováno v:
Applied Health Economics and Health Policy. 21:305-314
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e22f784d40560c0068bb243f0cb8f9be
https://doi.org/10.1007/s40258-022-00779-0
https://doi.org/10.1007/s40258-022-00779-0
Autor:
Victoria Lancaster, Marina Richardson, Francesca L Beaudoin, Patricia G Synnott, David M Rind, Belén Herce-Hagiwara, Jon D Campbell, Steven D Pearson
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 28:1316-1320
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::475f39f3c1e2f637a8c22d01d036030d
https://doi.org/10.18553/jmcp.2022.28.11.1316
https://doi.org/10.18553/jmcp.2022.28.11.1316
Autor:
David D. Kim, Lauren A. Do, Patricia G. Synnott, Tara A. Lavelle, Lisa A. Prosser, John B. Wong, Peter J. Neumann
Publikováno v:
Value in Health.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16aff6c92de4880c0ab4939fc4712d47
https://doi.org/10.1016/j.jval.2023.04.004
https://doi.org/10.1016/j.jval.2023.04.004
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 27:1613-1617
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47667331c4135d1f33ed381184a7a472
https://doi.org/10.18553/jmcp.2021.27.11.1613
https://doi.org/10.18553/jmcp.2021.27.11.1613
Autor:
Patricia G Synnott, Daniel A. Ollendorf, R. Brett McQueen, Steven D. Pearson, Jonathan D. Campbell
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 26:782-785
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, Commonwealth Fund, California Health Care Foundation, National Institute for Health Care Management (NIHCM), New England St...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b1610b74225dc778674bfb279e4226b
https://doi.org/10.18553/jmcp.2020.26.6.782
https://doi.org/10.18553/jmcp.2020.26.6.782
Autor:
Patricia G. Synnott, Pei-Jung Lin, Stacey S. Hickson, Christoph Glaetzer, Daniel A. Ollendorf
Publikováno v:
International Journal of Technology Assessment in Health Care. 38
Objectives The extent to which value assessments are uniquely deployed in any given geographic setting is variable. Increasingly, markets are seeking insights from external health technology assessments (HTAs) to assist with decisions surrounding the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16bceeb228ba39b8e7e23944f5c300fe
https://doi.org/10.1017/s026646232200023x
https://doi.org/10.1017/s026646232200023x
Autor:
Varun M. Kumar, David Rind, Melanie D Whittington, Judith M. E. Walsh, Jeffrey A. Tice, Patricia G Synnott, Steven D. Pearson, Ellie Adair, Jonathan D. Campbell
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 25:510-514
DISCLOSURES: Funding for this summary was contributed by the Laura and John Arnold Foundation, Blue Shield of California, and California Health Care Foundation to the Institute for Clinical and Eco...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9fb6c0cb4e5098e0f7993679f44a0da
https://doi.org/10.18553/jmcp.2019.25.5.510
https://doi.org/10.18553/jmcp.2019.25.5.510
Autor:
David Rind, Josh J. Carlson, Sonya Khan, Reiner Banken, Geri Cramer, Patricia G Synnott, Solomon J. Lubinga, Marita Zimmermann, Richard H. Chapman
Publikováno v:
Value in Health. 22:161-167
Objective The gene therapy voretigene neparvovec (VN) is the first Food and Drug Administration–approved treatment for vision loss owing to the ultra-rare RPE65-mediated inherited retinal disorders. We modeled the cost-utility of VN compared with s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e372f007ad50cd3cbf27e240829c76b9
https://doi.org/10.1016/j.jval.2018.09.2841
https://doi.org/10.1016/j.jval.2018.09.2841